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Abstract
Background The intravitreal anti-vascular
endothelial growth factor treatments
ranibizumab and aflibercept have proven
efficacy in clinical trials, but their real world
usage in central retinal vein occlusion
(CRVO) has not been assessed. We therefore
evaluated the treatment patterns of both
drugs in a US claims database.
Methods The IMS Integrated Data Warehouse
was used to identify the patients with CRVO
in the USA with claims for ranibizumab or
aflibercept between 24 September 2012 and 31
March 2014 with at least 12 months follow-up.
Patients were required to have had no anti-
VEGF treatment code for 6 months before
index (‘treatment-naive’). Mean numbers of
injections and non-injection visits to a treating
physician were compared with patients
receiving these treatments.
Results Patient characteristics were similar
for patients receiving ranibizumab (n¼ 206)
or aflibercept (n¼ 79) at index. The mean
(±SD) numbers of injections received by
patients treated with ranibizumab or
aflibercept were 4.4±2.8 and 4.7±2.9
(P¼ 0.38), respectively; the total number of
patient visits to their treating physician was
7.3±3.7 and 7.0±2.9 (P¼ 0.52), respectively.
For patients receiving one or more injections
(n¼ 238), the mean interval between
injections was 55.1 days (ranibizumab) and
54.2 days (aflibercept; P¼ 0.44).
Conclusions Our results suggest that, in
routine clinical practice, patients receive a
comparable number of injections in the first
year of treatment with ranibizumab or
aflibercept. This may have implications for
commissioning and service development of
CRVO care pathways.
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Introduction
Macular edema secondary to retinal vein
occlusion (RVO) can cause severe visual
impairment owing to obstruction of the retinal
vasculature, and is the second most common
retinal vascular disease.1,2 Occlusion of the
retinal veins causes an increase in retinal
capillary pressure resulting in upregulation of
vascular endothelial growth factor (VEGF)
expression and a consequent increase in
vascular permeability and new vessel
proliferation within the iris and anterior
chamber. As a result, blood and plasma are
discharged into the retina, often causing
complications including macular edema and
varying degrees of ischemia, potentially leading
to severe vision loss. Although occlusion of the
central retinal vein (central RVO (CRVO))
occurs less frequently than in branch veins, it is
associated with severe visual outcomes.
Anti-VEGF therapy is now the standard of
care for CRVO, replacing the previous
observation-only approach.3–5 Ranibizumab
(Lucentis; Genentech Inc., San Francisco, CA,
USA and Novartis Pharma AG, Basel,
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Switzerland) is a humanized, affinity-matured VEGF
antibody fragment that binds to and neutralizes all
isoforms of VEGF. Ranibizumab is recommended to be
given monthly based on the evidence from clinical trials.6
The efficacy of ranibizumab for the management of
CRVO has been reported in multiple studies including
the Randomized Study Comparing Ranibizumab to
Sham in Patients with Macular Edema Secondary to
CRVO (ROCC)7 and the Ranibizumab for the Treatment
of Macular Edema After CRVO Study (CRUISE);8,9
intravitreal injections of ranibizumab provided rapid
improvement in 6-month visual acuity and macular
edema following CRVO, with low rates of adverse
events.7,8 These improvements were largely maintained
with a subsequent 6 months of dosing as required (pro re
nata (PRN)).9 Ranibizumab was approved for treatment
of macular edema secondary to CRVO by the US Food
and Drug Administration (FDA) in June 2010.10
Aflibercept is a fully human, recombinant fusion
protein that targets VEGF-A, VEGF-B, and placental
growth factor. Aflibercept binds all isoforms of VEGF-A
with high affinity—a markedly higher affinity than that
of ranibizumab. Like ranibizumab, aflibercept is
recommended in the USA to be given as monthly
intravitreal injections.11 Patients should subsequently be
monitored regularly, and treatment should be resumed if
visual outcomes deteriorate. Two recent clinical trials
(VEGF Trap-Eye: Investigation of Efficacy and Safety in
CRVO (GALILEO)12,13 and VEGF Trap-Eye for macular
edema secondary to CRVO (COPERNICUS)14,15) have
shown that monthly intravitreal aflibercept treatment
was well tolerated and improved visual acuity after 6
months significantly more than sham injections; these
improvements were maintained with subsequent
monthly monitoring and PRN dosing.12 Aflibercept was
approved for the treatment of macular edema secondary
to CRVO in September 2012.16
Despite promising results from clinical trials as
described above, real world usage of aflibercept and
ranibizumab in CRVO has not yet been studied. This
study therefore aimed to assess the treatment patterns of
ranibizumab and aflibercept for the management of
macular edema secondary to CRVO in routine clinical
practice in the USA using a large, patient-level,
physician-entered claims database.
Materials and methods
This retrospective study was based on the analysis of US
physician-level claims data from the Integrated Data
Warehouse (IDW; managed by IMS Health, Plymouth
Meeting, PA, USA), a claims database that encompasses
B1 billion professional fee claims per year, representing
B80% of practicing eye care specialists (including over
13 000 ophthalmologists) and covering all 50 states.
Approximately 95% of claims submitted for payment from
these sources are available for analysis within 3 weeks.
The study included adult patients with a first medical
claim registered in the IDW with a procedure code for
intravitreal injection of ranibizumab or aflibercept
between 24 September 2012 and 31 March 2014, and with
a concomitant diagnosis of CRVO (recorded as a code
from the International Classification of Disease 9th
Revision Clinical Modification; ICD-9-CM 362.35); this
first claim was defined as the patient’s index date.
Patients were required to have at least 12 months of
follow-up data (post index date) within this study period
and a minimum of 6 months of available data in the IDW
before the index date. The physician administering the
index medication was required to have consistently
submitted medical claims to the IDW during the 6
months before the index date and during the follow-up
period (‘physician stability’ criteria). Patients were
excluded from the analysis if: their records indicated that
they had received an anti-VEGF injection during 6
months before the index date (ensuring ‘naivety’); if they
received more than one anti-VEGF drug within 12
months after the index date (to avoid the potential
confound of a patient being included in both groups).
The last assumption was relaxed in the sensitivity
analysis to assess the number of any anti-VEGF injections
received by patients starting on ranibizumab and
aflibercept.
The primary analysis assessed the number of injections
received, non-injection visits made and total visits (ie, the
sum of injection and non-injection visits) made by
treatment-naive patients (defined as having received no
anti-VEGF treatment claim in the 6 months before the
index date) who were treated continuously (ie, received
no other anti-VEGF therapy) with their index therapy for
at least 12 months (365 days). Mean dosing intervals
(number of days between the injections) were determined
for the first year of therapy for patients starting on either
treatment and receiving at least two injections.
Differences between the treatment patterns of
ranibizumab and aflibercept were assessed, and reported
P-values were adjusted for baseline characteristics.
Negative binomial regression was used to compare the
effect of patient characteristics on injection and visit
estimates for those treated continuously with
ranibizumab and aflibercept for at least 12 months.
A generalized estimating equation (GEE) model applied
at the patient level was used to compare the effect of
patient characteristics on dosing interval estimates for
patients having received two or more injections.
The nesting assumption is reviewed in the discussion
section. Finally, an autocorrelation of order 1 was used
for within-cluster correlation.
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Several sensitivity analyses were performed: we
assessed the mean number of injections, non-injection
visits, and total visits including anti-VEGFs other than
that given at index (‘any anti-VEGF’); and we assessed
the first 6 months of data to see if there were between-
group differences. We also assessed the baseline
characteristics of the patients receiving only one injection
compared with those receiving multiple injections, to
assess whether this patient subset could confound the
analyses. For continuous variables, between-group
statistical differences were assessed using unpaired
Student’s t-tests, with Po0.05 used to define a significant
difference. Categorical variables were assessed using
Fisher’s exact test.
Results
In total, 285 patients were treated continuously with their
index drug over 12 months (ranibizumab, n¼ 206;
aflibercept, n¼ 79; Figure 1). The two treatment groups
were comparable in terms of demographics or type of
health plan, and almost all patients received treatment
from an ophthalmologist (including retinal specialists)
(Table 1). The majority of patients in both the groups
(ranibizumab, 57%; aflibercept, 53%) were female, and
their median (interquartile range) ages were 74.0 (67.0–
81.0) years and 76.0 (70.0–81.0) years, respectively.
Cancer, cardiovascular disease, chronic pulmonary
disease, and diabetes mellitus were the only
comorbidities listed in the Charlson–Deyo comorbidity
index (CCI)17 that occurred in 45% of patients in either
group.
For patients treated continuously with ranibizumab or
aflibercept, the mean±SD number of injection visits
during the first 12 months of treatment (based on a
negative binomial model adjusting for characteristics;
Supplementary Table 1) was 4.4±2.8 and 4.7±2.9
(P¼ 0.38), respectively, and that of non-injection visits
was 2.8±2.6 and 2.2±2.1 (P¼ 0.06), respectively
(Figure 2). The total number of visits to the treating
physician in the 12 months after the index date was
7.3±3.7 and 7.0±2.9 (P¼ 0.52) for ranibizumab and
aflibercept, respectively. Patients received an injection on
the majority of their visits to their prescribing physician
(ranibizumab, 63%±26%; aflibercept, 67%±27%). For
patients receiving one injection or more (n¼ 238), the
mean interval between the injections was 55.1 days for
patients treated continuously with ranibizumab and 54.2
Final number of included patients:
 Ranibizumab = 206
Aflibercept = 79 
Exclusion criteria 
RVO
Primary inclusion criteria: all patients administered ranibizumab or
aflibercept between 24 September 2012 and 31 March 2014 for 
Included patients (administering physicians) 
Physician stability criteria applied for 6 months before index 
Did not have a minimum of 6 months of post-index records in IDW
Had a recorded code for anti-VEGF treatment in the 6 months before index 
Physician stability criteria applied for 12 months after index 
Did not have a minimum of 12 months of post-index records in IDW
Had a recorded code for anti-VEGF treatment in the 12 months after index
Did not have a concomitant ICD-9-CM diagnosis code for CRVO
19 796 (1749) 
4996 (471) 
4784 (468) 
2090 (369) 
810 (218) 
754 (213) 
640 (200) 
285 (147) 
Figure 1 Development and attrition of patient cohorts. CRVO, central retinal vein occlusion. ICD-9-CM, International Classification
of Disease 9th Revision Clinical Modification. IDW, integrated data warehouse. RVO, retinal vein occlusion. VEGF, vascular
endothelial growth factor.
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days for patients treated continuously with aflibercept
(P¼ 0.44). The details of the GEE model used to adjust
for the effects of patient characteristics on mean interval
length are shown in Supplementary Table 2.
Over half of the patients in each group had four or
more injections of their index drug within the first year of
treatment (ranibizumab, 55.3%; aflibercept, 60.8%;
Figure 3). Over 40% of all patients received four doses in
the first 6 months of therapy with their index treatment
(ranibizumab, 40.3%; aflibercept, 43.0%). Approximately
20% of all patients received five or more doses in the first
6 months of therapy with their index treatment
(ranibizumab, 22.3%; aflibercept, 19.0%).
When the inclusion criteria were extended to include
any additional anti-VEGF treatment claims during
follow-up (ranibizumab, n¼ 261; aflibercept, n¼ 93), the
numbers of all anti-VEGF injections received in the first
12 months of follow-up were 4.7±2.7 and 4.8±2.9
(P¼ 0.59) for patients starting on ranibizumab and
aflibercept, respectively (when adjusting for baseline
characteristics). The according number of non-injection
visits were 3.0±2.6 and 2.3±2.2 (Po0.05) and the total
number of visits were 7.6±3.6 and 7.1±2.9 (P¼ 0.25),
respectively.
Of patients receiving only one injection during
follow-up (ranibizumab, n¼ 35; aflibercept, n¼ 12),
78.7% made more than one subsequent non-injection
visit to their physician (ranibizumab, 77.1%; aflibercept,
83.3%; Figure 4). When comparing this subset of 47
patients who received only one injection during
Table 1 Baseline characteristics and patient demographics
Ranibizumab (n¼ 206) Aflibercept (n¼ 79) P-value
Age, median years (interquartile range) 74.0 (67.0–81.0) 76.0 (70.0–81.0)
Sex, n (%)
Female 117 (57) 42 (53) 0.60a
Male 89 (43) 37 (47)
Prescriber of index medication, n (%)
Ophthalmologist 206 (100) 78 (99) 0.28a
Other 0 (0) 1 (1)
Health plan, n (%)
Medicaid 4 (2) 0 (0) 0.08a
Medicare 141 (68) 64 (81)
Commercial 61 (30) 15 (19)
Geographic region, n (%)
Midwest 40 (19) 18 (23) 0.12a
Northeast 45 (22) 24 (30)
South 107 (52) 29 (37)
West 14 (7) 8 (10)
Charlson–Deyo comorbidities, n (%)
AIDS/HIV 0 (0) 0 (0)
Cancer 17 (8) 4 (5)
Chronic heart failure 6 (3) 4 (5)
Chronic pulmonary disease 12 (6) 9 (11)
Cardiovascular disease 10 (5) 5 (6)
Dementia 1 (0) 1 (1)
Diabetes with chronic complications 17 (8) 9 (11)
Diabetes with or without acute complications 19 (9) 9 (11)
Metastatic carcinoma 1 (0) 1 (1)
Mild liver disease 0 (0) 1 (1)
Moderate/severe liver disease 0 (0) 0 (0)
Myocardial infarction 0 (0) 1 (1)
Paraplegia/hemiplegia 0 (0) 0 (0)
Peptic ulcer disease 0 (0) 0 (0)
Peripheral vascular disease 1 (0) 3 (4)
Renal disease 9 (4) 1 (1)
Rheumatological disease 5 (2) 3 (4)
Charlson–Deyo comorbidity index, mean (95% CI) 0.6 (0.5–0.8) 0.8 (0.5–1.1) 0.361b
Abbreviations: AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus.
a Statistical differences between categorical variables assessed using Fisher’s exact test.
b Statistical differences between continuous variables assessed using unpaired Student’s t-tests.
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follow-up with those who received two or more
injections, these results were not significantly associated
with differences in sex, age, CCI, region, payer type, or
the specialty of the prescribing physician, although CCI
did approach significance (P¼ 0.05).
The majority of the 285 patients included in the
primary analysis received treatment in only one eye
throughout follow-up, with only 3.5% of patients
receiving bilateral treatment at any point during follow-
up (ranibizumab, 3.9%; aflibercept, 2.5%). When the
inclusion criteria were relaxed to include any anti-VEGF
treatment received during follow-up (n¼ 354), 4.5% of
patients were observed to have received bilateral
treatment at some point during follow-up (ranibizumab,
4.6%; aflibercept, 4.3%).
Of the 285 patients included in this study, none were
found to have a claim relating to glaucoma associated
with vascular disorders (ICD-9 365.63), diabetic macular
edema (DME; ICD-9 362.07) or neovascular age-related
macular degeneration (nAMD; ICD-9 362.50, 362.51,
362.52) in the 6 months before index. One patient had a
recorded claim for DME within the first year after
index; claims relating to glaucoma associated with
vascular disorders and nAMD were not observed
during follow-up.
Discussion
This patient-level claims database analysis is, to our
knowledge, the first to directly compare the patterns of
ranibizumab and aflibercept use when given for
treatment of CRVO. The main finding is that the number
of injections received and total number of visits made by
patients continuously treated with their index therapy
was not significantly different regardless of whether
patients started treatment with ranibizumab or
aflibercept. There were no discernible demographic
differences between patients in the ranibizumab and
aflibercept groups.
In the USA, both the anti-VEGF treatments assessed
presently are recommended to be given as monthly
intravitreal injections for the management of macular
edema secondary to CRVO. However, the presented
results suggest that very few patients receive this
regularity of injection throughout the first year of
treatment. Potentially, this is due at least in part to
improved visual outcomes in the patients receiving these
anti-VEGF treatments, as has been seen in clinical trials.
However, our time sensitivity analysis shows that even in
the first 6 months of treatment most patients do not
receive monthly anti-VEGF treatment as recommended
by the labels of ranibizumab and aflibercept.
Furthermore, we have shown that the likelihood of
bilateral treatment is low; less than 5% of patients in both
the groups were treated bilaterally in the year after index,
compared with reports that B10% of those with
unilateral CRVO will develop the condition bilaterally.1
The similarity of the injections given and total visits
made by patients in the ranibizumab and aflibercept
4.4 4.7 
2.8 2.2 
0
1
2
3
4
5
6
7
8
Ranibizumab
(n = 206) 
Aflibercept
(n = 79)
N
um
be
r o
f i
nj
ec
tio
ns
 re
ce
iv
ed
/
no
n-
in
je
ct
io
n 
vi
si
ts
 
Non-injection
visits (P = 0.06) 
Injection visits
(P = 0.38) 
Total visits
= 7.3 
Total visits
= 7.0 P = 0.52
Figure 2 Annual mean number of injections and annual mean
number of non-injection visits in the first year of therapy in
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groups suggest that physicians may be using these
treatments similarly in routine clinical practice. These
results are in alignment with those observed in other
ophthalmic indications, where the number of injections
and total visits made were similar whether patients
received ranibizumab or aflibercept. Another recent US
claims database study in patients with nAMD reported
that 5.8 (ranibizumab) and 5.5 (aflibercept) injections
were given annually.18 Furthermore, when the results
were extended to include the number of any intravitreal
anti-VEGF injections received during follow-up, the
mean number of injections received in the 12 months
after index was similar between treatment groups and
also similar to those received by patients receiving
continuous treatment with their index drug, suggesting
that the physicians may be using the two drugs
interchangeably.
Despite previous reports that a significant proportion
of patients with CRVO subsequently experience
neovascular glaucoma,19 we found no reports of
glaucoma associated with vascular disorders in the
6 months before index or during follow-up. Other
comorbidities such as DME and nAMD were also rare
during the study period, with only one observation of a
DME code during the follow-up period. The absence of
disease overlap indicates that the treatment patterns are
representative of patients with unambiguously
diagnosed CRVO.
Given that current market prices for ranibizumab and
aflibercept are similar (US wholesale acquisition costs per
0.5 mg vial: ranibizumab, $1950; aflibercept, $1850)20 and
that injections constitute the majority of the treatment
costs associated with these treatments, the observation
that the number of injections administered and physician
visits for each treatment is very similar suggests that
budgetary considerations for both treatments are likely to
be similar in routine clinical practice. Therefore, the
findings of this study represent important considerations
for payers when evaluating the cost effectiveness of these
treatments in the real world. These study findings also
highlight that the way new therapies are used in practice
may differ from recommendations based on the clinical
trials, and emphasize the importance of this type of post
approval observational study.
Owing to the relative recency of aflibercept approval
and the number of inclusion/exclusion criteria required
to product robust results, a large database with rapid
upload of data was essential in order to generate
sufficient data for analysis. The IDW is one of the largest
claims-based databases in the USA, and 95% of claims
are available for analysis within 3 weeks of submission.
We believe this to be the largest observational study of its
type to directly compare ranibizumab and aflibercept.
Our sensitivity analyses support the main findings and
suggest that the comparable observations made between
these two treatment groups are not confounded by
differences between groups in the first 6 months of
treatment; of the 55–60% of patients receiving four or
more injections in the first year after index treatment,
over 40% in each group received these injections in the
first 6 months of treatment. As no visual acuity data are
available in the claims database, it is not possible to
conclude that patients who only received one injection
did not need additional ones. However, the fact that the
vast majority of those patients had one or more follow-up
visits post injection is reassuring.
There are several limitations in this study. Like any
observational studies comparing two treatments, patient
inclusion could be subject to selection bias, particularly if
there are differences between patients receiving
ranibizumab and those receiving aflibercept. However,
the similarities of the available baseline characteristics
between both the groups of patients suggest that this is
not the case. Physicians’ approaches to treating CRVO
could differ from each other. One potential way to
address the physician-level specific would be to have run
a GEE model with multiple levels of cluster nesting
(physician and patient). However, in this data set, 147
physicians injected both ranibizumab and aflibercept
(average number of patients per physicians: 1.9); 118
(80.3%) of these physicians injected only one or two
patients. Therefore, there was not sufficient data to run a
meaningful analysis with two levels of nesting. As the
aflibercept treatment pool grows, the analysis may
become more meaningful. In addition, this study
involves a relatively small sample size after application
of the inclusion criteria, especially for aflibercept.
However, the similarity of the injection and total visit
results provide no suggestion that our findings are
underpowered, and even with extended analyses the
results are unlikely to demonstrate any clinically
meaningful differences in injections or total visits. This
study uses physician-entered claims codes to assess
treatment patterns; as such, a risk of misclassification is
inevitable, although we believe any such
misclassification applies to both treatment groups
equally. For example, the lack of neovascular glaucoma
during the study period is unlikely to mean that no such
events occurred, and more likely reflects that the
diagnosis was unrecorded or missed. Last, we were
unable to assess the effect of injection frequency on visual
outcomes. This is beyond the scope of this type of study
and requires further investigation.
In conclusion, this study is the first to directly compare
treatment patterns of ranibizumab and aflibercept
administered for the management of CRVO in routine
clinical practice in the USA. The results suggest that these
two therapies are not used as recommended by the labels
Ranibizumab and aflibercept use for central vein retinal occlusion in the USA
AJ Lotery and S Regnier
385
Eye
in the USA and that patients receive similar numbers of
injection regardless of the treatment with which they
initiate therapy. Further studies are warranted to link
these findings to visual outcomes and to evaluate
whether the treatment patterns observed in this US study
represent those in other countries.
Summary
What was known before
K Anti-VEGF treatments ranibizumab and aflibercept have
proven efficacy in clinical trials.
K The patterns of usage of these treatments in the real world
are not adequately understood.
What this study adds
K Patients receiving ranibizumab or aflibercept treatment
for management of macular edema secondary to retinal
vein occlusion receive a similar number of injections, and
make a similar number of visits to their treating physician.
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